We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Astrazeneca Plc | AZN | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 22.00 | 0.21% | 10,362.00 | 16:35:29 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 10,270.00 | 10,238.00 | 10,374.00 | 10,362.00 | 10,340.00 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Announcement Date | Type | Currency | Dividend Amount | Ex Date | Record Date | Payment Date |
|---|---|---|---|---|---|---|
| 06/02/2025 | Interim | GBP | 1.68 | 20/02/2025 | 21/02/2025 | 24/03/2025 |
| 21/02/2024 | Interim | GBP | 0.776 | 08/08/2024 | 09/08/2024 | 09/09/2024 |
| 08/02/2024 | Interim | GBP | 1.56 | 22/02/2024 | 23/02/2024 | 25/03/2024 |
| 09/02/2023 | Interim | GBP | 0.718 | 10/08/2023 | 11/08/2023 | 11/09/2023 |
| 09/02/2023 | Interim | GBP | 1.628 | 23/02/2023 | 24/02/2023 | 27/03/2023 |
| 10/02/2022 | Interim | GBP | 0.764 | 11/08/2022 | 12/08/2022 | 12/09/2022 |
| 10/02/2022 | Interim | GBP | 1.453 | 24/02/2022 | 25/02/2022 | 28/03/2022 |
| 11/02/2021 | Interim | GBP | 0.648 | 12/08/2021 | 13/08/2021 | 13/09/2021 |
| 05/11/2020 | Interim | GBP | 1.374 | 25/02/2021 | 26/02/2021 | 29/03/2021 |
| 24/10/2019 | Interim | GBP | 0.696 | 13/08/2020 | 14/08/2020 | 14/09/2020 |
| Top Posts |
|---|
Posted at 09/7/2025 09:59 by plootocrat when the AZN share price was 10,000.00p. Oh, and AZN has 11 manufacturing sites in the US. |
Posted at 12/5/2025 08:59 by wskill Not good AZN needs much higher pricing due to US courts awarding damages far beyond what is sensible and without proper science based evidence.Should this come into law there will no longer be a profitable market for anyone except USA owned pharma companies. Azn gets about 30% of revenue from the USA its the price that it sells at that counts and unfortunately its high in comparison to elsewhere in the world ,its not good for countries which cannot afford to pay more as the price they pay will rise to American price points. |
Posted at 06/5/2025 09:30 by undervaluedassets Tariffs should not be too bad ..Have huge manufacturing facilities in the US:- 17800 employees in the US. 17 research, development, manufacturing and commercial sites across the US. 9 billion doses of medicine produced in the US. In November 2024 AZN announced a 3.5 billion investment to expand in US manufacturing research and development capabilities in the US So in this crazy Trump-tariff world that we all find ourselves in AZN is well positioned. |
Posted at 16/4/2025 08:34 by plootocrat DanB45 I can't imagine anyone would want to do research on ADVFN as the information provided, even something as straightforward as dividend history, is so frequently out of date or just plain wrong. |
Posted at 12/4/2025 12:15 by waldron A STRONG BUY APPARENTLY |
Posted at 06/2/2025 09:52 by steeplejack There's enough in prospect to recommend AZN as a core holding in a UK equity portfolio.Revenue forecast to grow high single digits and core eps low double digits.The China situation re the authorities investigations seems manageable. "This year marks the beginning of an unprecedented, catalyst-rich period for our company, an important step on our Ambition 2030 journey to deliver $80 billion Total Revenue by the end of the decade. In 2025 alone, we anticipate the first Phase III data for seven new medicines, along with several important new indication opportunities for our existing medicines." |
Posted at 06/2/2025 07:18 by our haven Great results for the year. Uptick in dividend most welcome.Should make for a positive opening. |
Posted at 31/1/2025 15:08 by alphorn Following discussions with the current government, we (AZN) are no longer pursuing our planned investment at Speke. Several factors have influenced this decision including the timing and reduction of the final offer compared to the previous governments proposal. |
Posted at 13/1/2025 16:53 by philanderer AZN INVESTOR DEADLINE: AstraZeneca PLC Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitJan 13 2025 14:15 GMT SAN DIEGO , Jan. 13, 2025 /PRNewswire/ --Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of AstraZeneca PLC (NASDAQ: AZN) publicly traded securities between February 23, 2022 and December 17, 2024, inclusive (the "Class Period"), have until February 21, 2025 to seek appointment as lead plaintiff of the AstraZenecaclass action lawsuit. Captioned Saleh v. AstraZeneca PLC, No. 24-cv-11021 (C.D. Cal.), the AstraZenecaclass action lawsuit charges AstraZeneca as well as certain of AstraZeneca's top executives with violations of the Securities Exchange Act of 1934. |
Posted at 08/4/2024 14:47 by wad collector Really?Found 22 results: Blackhorse23 - 08 Apr 2024 - 11:28:43 - 6011 of 6012 AstraZeneca - AZN Money moved to APH Blackhorse23 - 05 Apr 2024 - 09:16:44 - 6009 of 6012 AstraZeneca - AZN Blackhorse23 - 21 Mar 2024 - 08:47:26 - 6002 of 6012 AstraZeneca - AZN Money moving to APH [LSE] , excellent profitable healthcare company Blackhorse23 - 21 Feb 2024 - 14:26:56 - 5995 of 6012 AstraZeneca - AZN Money moving to APH , excellent growth health care company Blackhorse23 - 12 Feb 2024 - 11:37:36 - 5981 of 6012 AstraZeneca - AZN Money moving to APH Blackhorse23 - 29 Jan 2024 - 15:32:08 - 5957 of 6012 AstraZeneca - AZN Blackhorse23 - 19 Jan 2024 - 11:52:35 - 5956 of 6012 AstraZeneca - AZN Ha ha hxxps://www.alliance Blackhorse23 - 18 Jan 2024 - 14:23:42 - 5954 of 6012 AstraZeneca - AZN Bought some APH today Blackhorse23 - 09 Jan 2024 - 11:01:43 - 5948 of 6012 AstraZeneca - AZN are they buying APH ?? |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
